Cochrane · systematic review · CD000205
Benzodiazepines for antipsychotic‐induced tardive dyskinesia
Bergman, H, Bhoopathi, PS, Soares‐Weiser, K · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
6
No studies
6
Included studies
NR
No studies 6 · 50%Ungraded 0 · 0%Very low 6 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Benzodiazepines compared with placebo for antipsychotic‐induced tardive dyskinesia
Population: psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: no clinically important improvement Benzodiazepines vs placebo | RR 1.12 [0.6, 2.09] | 2 studies · 32 participants | Very low Downgraded: risk of bias, imprecision |
Tardive dyskinesia: deterioration in symptoms Benzodiazepines vs placebo | RR 1.48 [0.22, 9.82] | 2 studies · 30 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effect: any adverse event Benzodiazepines vs placebo | no estimate extracted | NR | No studies |
Adverse effect: no clinically significant extrapyramidal adverse effects Benzodiazepines vs placebo | no estimate extracted | NR | No studies |
Acceptability of the treatment (measured by participants leaving the study early) Benzodiazepines vs placebo | RR 2.73 [0.15, 48.04] | 3 studies · 56 participants | Very low Downgraded: risk of bias, imprecision |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported Benzodiazepines vs placebo | no estimate extracted | NR | No studies |
Benzodiazepines compared with phenobarbital (as active placebo) for antipsychotic‐induced tardive dyskinesia
Population: psychiatric patients (mainly schizophrenia) with antipsychotic‐induced tardive dyskinesia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Tardive dyskinesia: no clinically important improvement Benzodiazepines vs phenobarbital (as active placebo) | RR 0.44 [0.2, 0.96] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Tardive dyskinesia: deterioration in symptoms ‐ not measured Benzodiazepines vs phenobarbital (as active placebo) | no estimate extracted | NR | No studies |
Adverse events: any Benzodiazepines vs phenobarbital (as active placebo) | RR 1.53 [0.97, 2.41] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Adverse effect: extrapyramidal symptoms ‐ not reported Benzodiazepines vs phenobarbital (as active placebo) | no estimate extracted | NR | No studies |
Acceptability of the treatment (measured by participants leaving the study early) Benzodiazepines vs phenobarbital (as active placebo) | no estimate extracted | 1 study · 21 participants | Very low Downgraded: risk of bias |
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured Benzodiazepines vs phenobarbital (as active placebo) | no estimate extracted | NR | No studies |